mesalamine + alpha-lipoic acid

A fixed-dose combination of **mesalamine** (also known as mesalazine or 5-aminosalicylic acid) and **alpha-lipoic acid**. Mesalamine is an anti-inflammatory drug widely used for the treatment and prevention of mild to moderate **ulcerative colitis**, acting primarily via inhibition of cyclooxygenase and lipoxygenase pathways, thereby reducing prostaglandin and leukotriene production in the colon. **Alpha-lipoic acid** is an endogenous antioxidant that serves as a cofactor for mitochondrial enzyme complexes and is recognized for its anti-inflammatory effects, potentially helping to reduce oxidative stress and modulate immune responses in colonic tissue. The rationale for the combination is to enhance anti-inflammatory and antioxidant effects, providing improved efficacy as an adjuvant regimen for ulcerative colitis and other inflammatory bowel diseases[1][3][4].